在治疗肝脏疾病的治疗中使用特里压素
Andrew R Scheinberg1, Paul Martin1, Joshua A Turkeltaub1
1Department of Medicine, Division of Digestive Health and Liver Diseases, University of Miami, Miami, FL, USA.
Expert opinion on pharmacotherapy
|August 3, 2023
概括
合成压缩类型的terlipressin被FDA批准用于肝综合征,其疗效优于其他药物. 它的血管收缩性质也表明其在治疗门高血压并发症方面的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 特里普林素是一种合成的血管压素类似物,最近被FDA批准用于肝综合征 (HRS).
- 它对血管压素受体起作用,导致状血管收缩并改善 perfusion.
- 它还通过对管起作用来表现出抗利尿活性.
研究的目的:
- 审查FDA批准的terlipressin用于HRS的使用情况.
- 讨论terlipressin的安全性和耐受性.
- 探索慢性肝病中的潜在替代应用.
主要方法:
- 对terlipressin的疗效,安全性和耐受性的现有数据的审查.
- 讨论关于非标签用途的当前研究.
主要成果:
- 特里普林在逆转HRS方面表现出比米多丁,八丁和上腺素更大的疗效.
- 它与HRS患者的短期生存率的改善有关.
- 指出了在水出血和其他门高血压并发症中的潜在应用.
结论:
- 特里压素是肝综合征的有效治疗方法,其生存结果得到改善.
- 需要进一步调查其用于慢性肝病其他并发症的使用情况.
相关概念视频
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420


